Pharma News, 2022

Shares of Cassava Sciences plunged Tuesday in premarket trading after multiple Alzheimer’s researchers raised new concerns about the company’s experimental Alzheimer’s treatment, simufilam. ...

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Merck Serono’s Tepmetko (tepotinib) for National Health Service (NHS) use in the treatment of certain adult pa...

The House Committee on Oversight and Reform has put out a staff report that calls out consulting firm McKinsey for simultaneously providing its services to pharmaceutical companies — including P...

Merck, known as MSD outside the United States and Canada, announced today that V116, the company’s investigational 21-valent pneumococcal conjugate vaccine, has received Breakthrough Therapy Des...

BriaCell Therapeutics Corp. , a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces that the U.S. Food and Drug Administration (FDA) has granted Fast...

Combining a retrospective analysis of clinical records with in-depth laboratory studies, researchers at The University of Texas MD Anderson Cancer Center have discovered that vitamin E can enhance...

The U.S. Food and Drug Administration has extended by three months its review of Regeneron Pharmaceuticals Inc's application for the full approval of its COVID-19 antibody therapy, the U.S. drugma...

Amneal Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Biologics License Application (BLA) for bevacizumab-maly, a biosimilar referenci...

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Biogen’s Vumerity (diroximel fumarate) for National Health Service (NHS) use for the treatment of relapsing-rem...

Shionogi has confirmed reports that its investigational COVID-19 drug, S-217622, led to fetal abnormalities in a preclinical study. ...

San Diego, Calif.-based Halozyme Therapeutics is purchasing Ewing, N.J.-headquartered Antares Pharma in a deal valued at approximately $960 million.

Bristol Myers Squibb’s blockbuster drug Opdivo (nivolumab) has met its primary endpoint of event-free survival in a phase 3 trial compared to chemotherapy alone in patients with resectable nonsma...